IL143555A0 - Method of administering a compound to multi-drug resistant cells - Google Patents

Method of administering a compound to multi-drug resistant cells

Info

Publication number
IL143555A0
IL143555A0 IL14355599A IL14355599A IL143555A0 IL 143555 A0 IL143555 A0 IL 143555A0 IL 14355599 A IL14355599 A IL 14355599A IL 14355599 A IL14355599 A IL 14355599A IL 143555 A0 IL143555 A0 IL 143555A0
Authority
IL
Israel
Prior art keywords
therapeutic compound
drug resistant
composition
administering
compound
Prior art date
Application number
IL14355599A
Other languages
English (en)
Original Assignee
Hadasit Med Res Service
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hadasit Med Res Service, Alza Corp filed Critical Hadasit Med Res Service
Publication of IL143555A0 publication Critical patent/IL143555A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL14355599A 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells IL143555A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300498P 1998-12-18 1998-12-18
PCT/US1999/030230 WO2000035422A2 (en) 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells

Publications (1)

Publication Number Publication Date
IL143555A0 true IL143555A0 (en) 2002-04-21

Family

ID=22347057

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14355599A IL143555A0 (en) 1998-12-18 1999-12-17 Method of administering a compound to multi-drug resistant cells

Country Status (12)

Country Link
US (2) US20040161457A1 (xx)
EP (1) EP1140022B8 (xx)
JP (1) JP2002532407A (xx)
AT (1) ATE385778T1 (xx)
AU (1) AU769569B2 (xx)
CA (1) CA2353593A1 (xx)
DE (1) DE69938148T2 (xx)
ES (1) ES2302391T3 (xx)
HK (1) HK1040633A1 (xx)
IL (1) IL143555A0 (xx)
MX (1) MXPA01006201A (xx)
WO (1) WO2000035422A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ014799A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using polymers
JP4922824B2 (ja) * 2000-04-03 2012-04-25 参天製薬株式会社 送達性物質およびそれを利用した薬物デリバリーシステム
CA2404737C (en) * 2000-04-03 2010-06-29 Santen Pharmaceutical Co., Ltd. Drug delivering substance containing polyalkylene glycol and phospholipid covalently bonded to drug
KR20050090987A (ko) * 2002-12-19 2005-09-14 알자 코포레이션 혈관신생 조직 성장 치료 방법
EP2529758A3 (en) 2003-01-27 2013-01-02 Endocyte, Inc. Vitamin receptor binding drug delivery conjugates
CN100423778C (zh) * 2003-11-25 2008-10-08 上海复旦张江生物医药股份有限公司 用于上载抗肿瘤药物的脂质体载体及其制备方法和应用
WO2006012527A1 (en) 2004-07-23 2006-02-02 Endocyte, Inc. Bivalent linkers and conjugates thereof
WO2007130462A2 (en) * 2006-05-04 2007-11-15 Alza Corporation Treating micrometastases using immunoliposomes comprising a chemotherapeutic agent, a targeting ligand and a hydrophilic polymer
CA2680535C (en) 2007-03-14 2016-09-20 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
EP2125024B1 (en) * 2007-03-23 2013-02-13 TO-BBB Holding B.V. Targeted intracellular delivery of antiviral agents
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
WO2009002993A1 (en) 2007-06-25 2008-12-31 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
EP2440250A1 (en) 2009-06-11 2012-04-18 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
SI2731591T1 (sl) 2011-07-13 2021-02-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Liposomi ko-inkapsulirajoči bifosfonat in amfipatično sredstvo
PT2789348T (pt) 2011-12-07 2021-11-11 Univ Do Minho Lipossomas e método de produção correspondente
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
GB201215289D0 (en) * 2012-08-28 2012-10-10 Medical Res Council Nanoparticle formulation
US9950074B2 (en) * 2012-10-12 2018-04-24 Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin Composition and delivery vehicle for active agents and methods therefor
WO2014062697A2 (en) 2012-10-16 2014-04-24 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
CN106420615B (zh) * 2016-07-05 2021-01-05 广东药科大学 一种靶向脂质体骨架材料及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5858397A (en) * 1995-10-11 1999-01-12 University Of British Columbia Liposomal formulations of mitoxantrone
US5804445A (en) * 1996-01-11 1998-09-08 Board Of Regents, The University Of Texas System High affinity mutants of nuclear factor-interleukin 6 and methods of use therefor
WO1998013072A1 (en) * 1996-09-24 1998-04-02 Thomas Jefferson University Compositions for and methods of treating multiple drug resistance
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
US6162810A (en) * 1997-11-17 2000-12-19 The Regents Of The University Of California Inadone and tetralone compounds for inhibiting cell proliferation
US6426086B1 (en) * 1998-02-03 2002-07-30 The Regents Of The University Of California pH-sensitive, serum-stable liposomes
IT1315253B1 (it) * 1999-10-22 2003-02-03 Novuspharma Spa Preparazione liposomiale di 6,9-bis-(2-amminoetil)ammino|benzog|isochinolin-5,10-dione dimaleato
ES2308256T3 (es) * 2003-09-24 2008-12-01 Wyeth Holdings Corporation 6-aril-7-halo-imidazo(1,2-a)pirimidinas como agentes anticancerosos.

Also Published As

Publication number Publication date
MXPA01006201A (es) 2003-06-06
EP1140022B1 (en) 2008-02-13
US20040161457A1 (en) 2004-08-19
ATE385778T1 (de) 2008-03-15
US20060062842A1 (en) 2006-03-23
HK1040633A1 (en) 2002-06-21
AU1940400A (en) 2000-07-03
CA2353593A1 (en) 2000-06-22
JP2002532407A (ja) 2002-10-02
EP1140022A2 (en) 2001-10-10
WO2000035422A2 (en) 2000-06-22
EP1140022B8 (en) 2008-10-15
DE69938148D1 (de) 2008-03-27
AU769569B2 (en) 2004-01-29
ES2302391T3 (es) 2008-07-01
DE69938148T2 (de) 2009-02-26
WO2000035422A3 (en) 2000-10-12

Similar Documents

Publication Publication Date Title
EP1140022B8 (en) Method of administering a compound to multi-drug resistant cells
IL142573A0 (en) Liposome-entrapped topoisomerase inhibitors
WO1998016202B1 (en) Fusogenic liposome composition and method
WO1999039741A3 (en) Systemic delivery of serum stable plasmid lipid particles for cancer therapy
CA2193502A1 (en) Sphingosomes for enhanced drug delivery
WO2000045792A8 (en) Hydrogel particle formulations
WO2000007979A3 (en) Compounds and compositions for delivering active agents
AU5408098A (en) Oral morphine multiparticulate formulation
WO2002022000A3 (en) Targeted alpha particle therapy using actinium-225 conjugates
CA2338358A1 (en) Compounds and compositions for delivering active agents
WO2001080843A3 (en) Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
UA50719C2 (uk) Проліки для терапії пухлин і запальних захворювань
CA2628857A1 (en) Formulation and method for treating neoplasms by inhalation
CA2208206A1 (en) Composition for treating tumors comprising lactose and a saccharide conjugate of a cytotoxic phenolic compound
CA2122519A1 (en) Cancer Treatment and Metastasis Prevention
WO1999013816A3 (en) Liposomal camptothecin formulations
CA2202531A1 (en) Lyophilizate of lipid complex of water insoluble camptothecins
JP2002532407A5 (xx)
Zou et al. Effectiveness of water soluble poly (L-glutamic acid)-camptothecin conjugate against resistant human lung cancer xenografted in nude mice
WO1999022722A3 (en) Use of macrolides for the treatment of cancer and macular degeneration
CA2108963A1 (en) Compositions and Methods for Therapy and Prevention of Cancer, Aids and Anemia
WO1998030709A3 (en) Non-immunogenic prodrugs and selectable markers for use in gene therapy
Sharma et al. Modulation of human ovarian tumor cell sensitivity to N-(phosphonacetyl)-L-aspartate (PALA) by liposome drug carriers
CA2225807A1 (en) Use of lamellarin-class alkaloids in methods of treatment
CA2280773A1 (en) Methods for the administration of amifostine